European HTA Highlights: IQWiG Focuses On Indications, Benefits; NICE Still Obsessed With Cost Controls
Executive Summary
Germany’s IQWiG is concentrating on product benefits in its reviews, though is still expecting carefully tailored studies from sponsors. But industry’s concern in England continues to focus on NICE’s obsession with saving the NHS money – meaning pharma must make innovation cheaper to succeed.